Controversy in FLT3-ITD AML: Is the Optimal Duration of Maintenance Therapy Clearly Defined?
Friday, October 2, 2026
13:45–14:45 CEST
Meeting objectives
- Review the evidence supporting FLT3 inhibitor maintenance therapy in FLT3-ITD AML
- Evaluate the factors influencing decisions on the duration of FLT3 inhibitor maintenance therapy
- Discuss how MRD assessment can optimise decisions around maintenance to improve outcomes
Chair
- Professor Felicitas Thol (Hannover Medical School, Germany)
Speakers
- Professor Federico Lussana (Università degli Studi di Milano, Italy)
- Doctor Pramila Krishnamurthy (King’s College London, UK)
| AGENDA | |
|---|---|
| 13:45–13:50 (5 min) |
Welcome and Introduction Professor Felicitas Thol |
| 13:50–14:10 (20 min) |
No: Doctor Pramila Krishnamurthy |
| 14:10–14:30 (20 min) |
Yes: Professor Federico Lussana |
| 14:30–14:45 (15 min) |
Panel Discussion and Closing Remarks All faculty and Chair |
MED-EU-QUI-00372 | Date of preparation: August 2026
This satellite symposium is organised and funded by Daiichi Sankyo and is intended for HCPs. Daiichi Sankyo Europe GmbH, Zielstattstr. 48, 81379 Munich, Germany. © 2025 Daiichi Sankyo Europe GmbH.
